Literature DB >> 6722775

Interferon-induced cell cycle changes in human hematopoietic cell lines and fresh leukemic cells.

G Roos, T Leanderson, E Lundgren.   

Abstract

A panel of 26 human hematopoietic cell lines was tested for sensitivity to growth inhibition towards interferon-alpha (IFN-alpha) by estimating the effects on cell cycle phase distribution using flow cytometry analysis. The proportion of proliferating cells was assessed by studying the fractional increase of cells in mitosis during a 24-hr vinblastine block. Of 26 cell lines tested, 17 were sensitive to IFN-alpha, and the main cell cycle effect was accumulation in the G0-G1 phase. One Burkitt's lymphoma line, Namalwa, showed a decreased rate of progress through S without any G0/G1 accumulation. Three of the cell lines were also tested with IFN-beta and with IFN-alpha 2 produced by recombinant DNA technology. The latter IFN did not affect one of the cell lines; otherwise, the results were similar to those of IFN-alpha. Six of 16 clinical specimens from patients with hematopoietic neoplasias were IFN-sensitive, all displaying a G0-G1 block. Our results indicate that IFN sensitivity is an individually linked property unrelated to cell origin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6722775

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Stochastic receptor expression determines cell fate upon interferon treatment.

Authors:  Doron Levin; Daniel Harari; Gideon Schreiber
Journal:  Mol Cell Biol       Date:  2011-06-20       Impact factor: 4.272

2.  Interferon modulates the messenger RNA of G1-controlling genes to suppress the G1-to-S transition in Daudi cells.

Authors:  H Yamada; K Ochi; S Nakada; S Takahara; T Nemoto; T Sekikawa; J Horiguchi-Yamada
Journal:  Mol Cell Biochem       Date:  1995-11-22       Impact factor: 3.396

Review 3.  Apoptosis and cell growth inhibition as antitumor effector functions of interferons.

Authors:  H Strander
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

4.  Effect of interferon-beta on the cell cycle of human glioma cell line U-251 MG: flow cytometric two-dimensional (BrdU/DNA) analysis.

Authors:  S Genka; N Shitara; Y Tsujita; Y Kosugi; K Takakura
Journal:  J Neurooncol       Date:  1988-12       Impact factor: 4.130

5.  Changes of cell cycle-regulating genes in interferon-treated Daudi cells.

Authors:  H Yamada; K Ochi; S Nakada; T Nemoto; J Horiguchi-Yamada
Journal:  Mol Cell Biochem       Date:  1994-07-27       Impact factor: 3.396

6.  In vitro chemosensitivity tests on human tumor xenografts by clonogenic assay: the combined use of mitomycin C with alpha-interferon or gamma-interferon.

Authors:  N Hirabayashi; K Yoshinaka; Y Nosoh; T Toge; M Niimoto; T Hattori; T Ohkita
Journal:  Jpn J Surg       Date:  1985-07

7.  The effect of recombinant alpha-interferon on natural killer cell activity and clinical course in patients with myelodysplastic syndrome.

Authors:  X Yataganas; G Eliopoulos; S Koulocheri; N Viniou; E Plata; P Panagiotidis; G Vayopoulos; J Meletis; P Fessas
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

8.  Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha.

Authors:  Carolina Scagnolari; Pompea Zingariello; Jacopo Vecchiet; Carla Selvaggi; Delia Racciatti; Gloria Taliani; Elisabetta Riva; Eligio Pizzigallo; Guido Antonelli
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

9.  Antiproliferative Properties of Type I and Type II Interferon.

Authors:  Joseph Bekisz; Samuel Baron; Corey Balinsky; Angel Morrow; Kathryn C Zoon
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-30

10.  Temporal dynamics of the transcriptional response to dengue virus infection in Nicaraguan children.

Authors:  Stephen J Popper; Aubree Gordon; Minghsun Liu; Angel Balmaseda; Eva Harris; David A Relman
Journal:  PLoS Negl Trop Dis       Date:  2012-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.